1. Home
  2. CURI vs BMEA Comparison

CURI vs BMEA Comparison

Compare CURI & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CuriosityStream Inc.

CURI

CuriosityStream Inc.

HOLD

Current Price

$2.91

Market Cap

165.0M

ML Signal

HOLD

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.25

Market Cap

132.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CURI
BMEA
Founded
N/A
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Movies/Entertainment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
165.0M
132.6M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
CURI
BMEA
Price
$2.91
$1.25
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
6
Target Price
$5.83
★ $9.83
AVG Volume (30 Days)
739.8K
★ 2.1M
Earning Date
05-06-2026
05-12-2026
Dividend Yield
★ 10.36%
N/A
EPS Growth
54.17
★ 69.19
EPS
★ 0.12
N/A
Revenue
★ $78,043,000.00
N/A
Revenue This Year
$14.91
N/A
Revenue Next Year
$12.91
N/A
P/E Ratio
$24.25
★ N/A
Revenue Growth
★ 9.52
N/A
52 Week Low
$2.30
$0.87
52 Week High
$5.38
$2.99

Technical Indicators

Market Signals
Indicator
CURI
BMEA
Relative Strength Index (RSI) 52.99 33.03
Support Level $2.81 $1.17
Resistance Level $2.97 $1.47
Average True Range (ATR) 0.12 0.15
MACD 0.02 -0.08
Stochastic Oscillator 57.27 0.00

Price Performance

Historical Comparison
CURI
BMEA

About CURI CuriosityStream Inc.

CuriosityStream Inc is a media and entertainment company. It offers premium video programming across the principal categories of factual entertainment, including science, history, society, nature, lifestyle, and technology. The firm's products and services are Direct to Consumer Business, Partner Direct Business, Bundled Distribution, Content Licensing, and Others. The majority of the revenue comes from the direct business and Content licensing. Geographically, the company generates the majority of its revenue from the United States.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

Share on Social Networks: